OtherBASIC SCIENCE INVESTIGATIONS
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models
Gang Niu, Zibo Li, Jin Xie, Quynh-Thu Le and Xiaoyuan Chen
Journal of Nuclear Medicine July 2009, 50 (7) 1116-1123; DOI: https://doi.org/10.2967/jnumed.109.061820
Gang Niu
Zibo Li
Jin Xie
Quynh-Thu Le
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 50, Issue 7
July 2009
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models
Gang Niu, Zibo Li, Jin Xie, Quynh-Thu Le, Xiaoyuan Chen
Journal of Nuclear Medicine Jul 2009, 50 (7) 1116-1123; DOI: 10.2967/jnumed.109.061820
Jump to section
Related Articles
Cited By...
- Comprehensive Network and Structural Analysis of Bovine Papillomavirus, Squamous Cell Carcinoma Markers, and Elucidation of Efficacy Mechanisms of Phytochemicals from Thuja Occidentalis
- Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers
- Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models
- Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII
- Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
- In vivo albumin labeling and lymphatic imaging
- Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab')2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model
- In Vivo Labeling of Serum Albumin for PET
- Glypican-3-Targeted 89Zr PET Imaging of Hepatocellular Carcinoma
- A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma
- Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics
- Inactivation of HNSCC Cells by 90Y-Labeled Cetuximab Strictly Depends on the Number of Induced DNA Double-Strand Breaks
- Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic
- PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1-Targeted 89Zr-Labeled Panitumumab
- 18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy
- Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
- Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab
- Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma
- Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma